id,tipo,text_start,text_end,text
10080213,Premise,1330,1511,Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.,
10080213,Premise,1512,1659,Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.,
10080213,Premise,1660,1808,Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.,
10080213,Premise,1809,1939,Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).,
10080213,Premise,1940,2046,Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.,
10080213,Premise,2047,2205,A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.,
10080213,Premise,2302,2430,In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.,
10080213,Claim,2593,2757,in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.,
10080213,Claim,2440,2592,further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,,
10599663,Premise,1027,1125,The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).,
10599663,Premise,1259,1512,The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.,
10599663,Premise,1513,1644,Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.,
10599663,Claim,1720,1852,The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.,
10599663,Claim,1853,2001,Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.,
10682964,Claim,1745,1927,Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.,
10682964,Claim,1928,2063,Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.,
10682964,Claim,2064,2149,Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.,
10682964,Premise,966,1185,Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.,
10682964,MajorClaim,2,99,Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.,
10682964,Premise,839,965,All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.,
10682964,Premise,1619,1680,Adverse events were nonserious and resolved without sequelae.,
10837379,Premise,620,698,The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.,
10837379,Premise,513,619,After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.,
10837379,Premise,699,786,The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).,
10837379,Premise,952,1118,The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).,
10837379,Claim,1119,1175,Both drugs were well tolerated systemically and locally.,
10837379,Claim,1176,1324,Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.,
10837379,Premise,787,951,Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).,
10877373,Premise,831,933,Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.,
10877373,Premise,934,1025,The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.,
10877373,Premise,1026,1072,Few patients reported a specific adverse event,
10877373,Premise,1078,1232,with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.,
10877373,Premise,1233,1308,No significant chronotropic effects on the heart were seen with brimonidine,
10877373,Premise,1316,1408,small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.,
10877373,Premise,1409,1494,Mean systolic and diastolic blood pressure remained relatively stable in both groups.,
10877373,Premise,1495,1574,Quality of life remained stable, with no significant between-group differences.,
10877373,Claim,1575,1761,As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.,
10877373,MajorClaim,1762,1868,Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.,
10901475,Premise,811,912,For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).,
10901475,Premise,913,1099,IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.,
10901475,Premise,1100,1277,The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.,
10901475,Premise,1278,1340,Two eyes treated with latanoprost showed an iris color change.,
10901475,Premise,1341,1463,Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).,
10901475,Claim,1464,1666,From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.,
10901475,Claim,1667,1744,Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.,
10901475,Claim,1745,1810,The increase in iris pigmentation requires further investigation.,
11020403,Premise,480,708,With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.,
11020403,Premise,709,890,Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.,
11020403,Premise,891,1106,The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).,
11020403,Premise,1116,1188,the Ahmed implant group had a greater adjunctive medication requirement.,
11020403,Premise,1189,1321,On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).,
11020403,Premise,1425,1498,Lower mean intraocular pressures were noted for the trabeculectomy group.,
11020403,Premise,1499,1634,All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.,
11020403,Premise,1322,1424,There was no statistically significant difference in the rate of complications between the two groups.,
11124286,Premise,451,609,Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.,
11124286,Premise,610,701,In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.,
11124286,Premise,702,847,The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.,
11124286,Premise,848,970,The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.,
11124286,Premise,1025,1266,Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.,
11124286,Claim,1267,1366,Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.,
11124286,Premise,971,1024,These differences were not statistically significant.,
11148810,Claim,2,123,Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.,
11148810,Premise,809,954,After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);,
11148810,Premise,955,1074,the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.,
11148810,Premise,1075,1191,Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).,
11148810,Premise,1192,1218,Study attrition was large.,
11148810,Premise,1219,1329,Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.,
11148810,Premise,1330,1484,IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).,
11148810,Claim,1485,1682,In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.,
11148810,Premise,1683,1758,The intent-to-treat analysis showed no difference between treatment groups.,
11148810,Premise,1759,1837,The high attrition shows the difficulties associated with very long follow-up.,
11158795,Premise,634,806,After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.,
11158795,Premise,807,957,With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjects undergoing trabeculectomy.,
11158795,Claim,958,1120,According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients.,
11158796,Claim,1270,1435,Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.,
11158796,Premise,752,879,From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).,
11158796,Premise,880,1047,The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.,
11158796,Premise,1048,1194,A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.,
11167277,Claim,847,1010,Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.,
11167277,Premise,376,530,Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.,
11167277,Premise,531,613,These differences were statistically significant (p<0.05) at the end of the study.,
11167277,Premise,614,846,After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.,
11336940,Premise,1031,1300,After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.,
11336940,Premise,1301,1445,The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].,
11336940,Premise,1446,1658,Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.,
11336940,Premise,1659,1731,Adverse ocular symptoms and findings were mild in both treatment groups.,
11336940,Premise,1732,1807,Eye redness and ocular irritation were the most frequently reported events.,
11336940,Claim,1808,2031,Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.,
11336940,Claim,2032,2094,Both drugs were well tolerated with few ocular adverse events.,
11558817,Premise,960,1046,The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).,
11558817,Premise,1047,1195,The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.,
11558817,Premise,1196,1408,The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).,
11558817,Claim,1409,1473,Drugs administered in both treatment groups were well tolerated.,
11558817,Claim,1474,1646,This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.,
11730649,Claim,2055,2278,Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.,
11730649,Premise,886,1047,Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.,
11730649,Premise,1048,1207,The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.,
11730649,Premise,1208,1311,These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).,
11730649,Premise,1312,1553,The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.,
11730649,Premise,1554,1705,Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.,
11730649,Premise,1706,1782,No iris pigmentation changes were observed in any patient during this study.,
11730649,Premise,1783,1983,There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.,
11730649,Premise,1984,2054,There were no serious adverse events reported for any treatment group.,
11813932,Claim,2824,2941,Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.,
11813932,Premise,1375,1545,After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.,
11813932,Premise,1546,1690,The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).,
11813932,Premise,1691,1905,Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).,
11813932,Premise,1906,2083,In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);,
11813932,Premise,2143,2304,Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).,
11813932,Premise,2305,2404,At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.,
11813932,Premise,2405,2563,In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.,
11813932,Claim,2564,2712,This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.,
11813932,Premise,2713,2823,In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.,
11813932,Premise,2084,2142,however, the difference was not statistically significant.,
11912355,Premise,879,1165,From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).,
11912355,Premise,1166,1280,This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).,
11912355,Premise,1281,1465,Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.,
11912355,Claim,1466,1605,Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.,
11912355,Claim,1606,1746,However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.,
11912355,Claim,1747,1852,Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.,
12169965,Claim,1279,1413,In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.,
12169965,Premise,771,951,One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.,
12169965,Premise,952,1162,The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).,
12169965,Premise,1163,1278,The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.,
12169965,Claim,1423,1493,postoperative complications are more frequent after filtering surgery.,
12383808,Premise,915,1058,A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).,
12383808,Premise,1059,1196,At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).,
12383808,Premise,1197,1291,The most common complications in each group were persistent choroidal effusions and bleb leak.,
12383808,Claim,1292,1457,Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.,
12470755,Claim,1390,1431,Both agents were safe and well tolerated.,
12470755,Claim,1254,1389,Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.,
12470755,Premise,879,1185,The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.,
12470755,Premise,1186,1253,No serious adverse event related to either medication was reported.,
12644943,Claim,1762,1903,the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.,
12644943,Premise,1015,1154,Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.,
12644943,Premise,1155,1302,The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.,
12644943,Premise,1303,1414,Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.,
12644943,Premise,1415,1493,The betaxolol-treated group had significantly lower post-treatment IOP values.,
12644943,Premise,1494,1585,Converters had significantly higher pre- and post-treatment IOP values than non-converters.,
12644943,Premise,1586,1654,Betaxolol significantly lowered the IOP level compared with placebo.,
12644943,Premise,1655,1753,Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.,
12660585,Premise,2558,2755,At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.,
12660585,Premise,2756,2856,At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.,
12660585,Premise,2857,2943,At each evaluation time, the two unilateral t tests were highly significant (p<0.005),,
12660585,Premise,3075,3234,Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.,
12660585,Premise,3235,3376,Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.,
12660585,Premise,3377,3525,Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.,
12660585,Premise,3526,3612,A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.,
12660585,Premise,3613,3815,Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.,
12660585,Claim,3857,4039,The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.,
12660585,Claim,4228,4385,The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.,
12660585,Premise,3816,3856,No serious adverse events were reported.,
12750084,Premise,795,967,At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);,
12750084,Premise,968,1135,an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).,
12750084,Premise,1136,1480,Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases,
12750084,Premise,1482,1811,Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.,
12750084,Premise,1812,1844,No patient required reoperation.,
12750084,Premise,1845,1985,Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.,
12750084,Claim,1986,2090,Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.,
12750084,Claim,2091,2266,Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.,
12908569,Claim,2524,2588,It has a safe systemic profile with minimum effect on the heart.,
12908569,Premise,892,1018,The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).,
12908569,Premise,771,891,At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.,
12908569,Premise,1019,1200,At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.,
12908569,Premise,1201,1371,At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.,
12908569,Premise,1456,1621,The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).,
12908569,Premise,1622,1725,17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.,
12908569,Premise,1726,1792,Ocular allergy occurred in 10.3% of patients in brimonidine group.,
12908569,Premise,1793,1895,No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.,
12908569,Premise,1896,1980,Mean systolic and diastolic blood pressure remained relatively stable in both groups,
12908569,Premise,2234,2361,Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.,
12908569,Claim,2362,2523,Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.,
12908569,Premise,2141,2233,The mean heart rate in the brimonidine group was relatively unchanged over the study period.,
12908569,Premise,1981,2061,except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.,
14644719,Claim,1682,1865,In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.,
14644719,Premise,839,942,Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.,
14644719,Premise,943,1132,At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).,
14644719,Premise,1133,1251,At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.,
14644719,Premise,1252,1495,At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).,
14644719,Premise,1496,1681,Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.,
14704542,Claim,1624,1806,In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up.,
14704542,Premise,1067,1623,Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).,
14704542,Premise,893,1066,Surgical success rate was defined as an IOP reduction greater than or equal to 30% and final IOP more than 5 mm Hg and less than 22 mm Hg, without devastating complications.,
14982045,Claim,1925,2016,The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.,
14982045,Premise,954,1221,At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.,
14982045,Premise,1222,1459,After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.,
14982045,Premise,1460,1642,The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.,
14982045,Claim,1782,1832,Both treatments were well tolerated over 3 months,,
14982045,Premise,1643,1781,The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.,
14982045,Premise,1833,1924,although ocular stinging occurred more frequently with the dorzolamide/timolol combination.,
15037889,Premise,683,812,Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).,
15037889,Premise,813,982,In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.,
15037889,Premise,983,1130,The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.,
15037889,Premise,1131,1292,No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.,
15037889,Premise,1293,1378,There were no patients who dropped out due to the side effects of treatment regimens.,
15037889,Claim,1379,1508,Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients,
15037889,Claim,1510,1566,both showed similar effects on visual field performance.,
15177955,Claim,1901,2013,Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.,
15177955,Premise,981,1225,After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).,
15177955,Premise,1226,1450,When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.,
15177955,Premise,1451,1588,There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).,
15177955,Premise,1589,1692,After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.,
15177955,Premise,1693,1794,Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.,
15177955,Premise,1795,1900,There was no significant difference between the incidences of postoperative complications in both groups.,
15220019,Claim,2408,2488,Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.,
15220019,Premise,1493,1668,Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.,
15220019,Premise,1425,1492,Mean baseline diurnal IOP values were similar between the 2 groups.,
15220019,Premise,1669,1817,Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).,
15220019,Premise,1818,2012,After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).,
15220019,Premise,2013,2125,Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).,
15220019,Claim,2126,2307,In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,,
15220019,Claim,2308,2407,except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.,
15234141,Claim,1433,1592,Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.,
15234141,Premise,659,886,Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.,
15234141,Premise,887,942,A decrease in IOP of 56.6% and 65.9% had been achieved.,
15234141,Premise,943,1108,Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.,
15234141,Premise,1109,1214,Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.,
15234141,Premise,1215,1432,More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.,
15474813,Claim,1390,1452,the complication rate was lower in the viscocanalostomy group.,
15474813,Premise,569,711,At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).,
15474813,Premise,712,935,Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).,
15474813,Premise,936,1156,Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).,
15474813,Premise,1157,1300,Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).,
15474813,Claim,1301,1380,Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.,
15598478,Premise,1996,2205,A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).,
15598478,Premise,2206,2458,PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).,
15598478,Claim,2682,2905,patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.,
15598478,Premise,2496,2650,Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).,
15598478,Claim,2459,2495,Both treatments were well tolerated.,
1565457,Premise,308,608,Six months after surgery, intraocular pressures averaged 10.9 +/- 5.3 mmHg (mean +/- standard deviation) in the MMC-treated eyes versus 14.2 +/- 5.5 mmHg in the 5-FU-treated eyes (P = 0.08) and were less than or equal to 12 mmHg in 60.0% of MMC-treated eyes and 21.1% of 5-FU-treated eyes (P = 0.03).,
1565457,Premise,806,922,Drug-induced corneal epithelial defects were seen in nine 5-FU-treated eyes and in no MMC-treated eyes (P = 0.0004).,
1565457,Claim,923,1168,These results suggest that intraoperative MMC may be a viable alternative to postoperative 5-FU, with lower overall intraocular pressures, decreased dependence on postoperative ocular antihypertensive medications, and decreased corneal toxicity.,
15741820,Premise,914,1091,At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).,
15741820,Premise,1092,1189,The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).,
15741820,Premise,1190,1306,Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.,
15741820,Claim,1307,1488,Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.,
15741820,Claim,1489,1593,During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.,
16899528,Premise,548,825,No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups.,
16899528,Claim,826,963,SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma.,
17083910,Premise,1128,1336,Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.,
17083910,Claim,1410,1497,there was less need for supplemental medical therapy following trabeculectomy with MMC.,
17083910,Premise,978,1127,The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).,
17083910,Claim,1337,1404,Both surgical procedures produced similar IOP reduction at one year,
17083910,Premise,839,977,The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).,
17244215,Premise,967,1134,In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.,
17244215,Premise,1196,1313,The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.,
17244215,Claim,1314,1391,Both bimatoprost and the timolol-dorzolamide combination were well tolerated.,
17244215,Claim,1392,1497,Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.,
17244215,Premise,1135,1195,The difference was not statistically significant (p = 0.48).,
17293790,Premise,994,1198,Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.,
17293790,Premise,1199,1372,IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).,
17293790,Premise,1373,1468,The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).,
17293790,Claim,1484,1584,we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.,
17397924,Claim,1449,1682,There was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phacoemulsification and intraocular lens implantation in patients with primary open-angle glaucoma.,
17397924,Premise,1023,1199,At 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).,
17397924,Premise,540,938,Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7). Mean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.,
17601060,Premise,817,914,Intraocular pressure was significantly reduced during the entire follow-up period in both groups.,
17601060,Premise,915,1088,In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).,
17601060,Claim,1257,1406,The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.,
17601060,Claim,1492,1603,the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.,
17601060,Claim,1407,1491,Because the efficacy of both drugs was equivalent, with an identical safety profile,,
17601060,Premise,1089,1256,In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).,
17825417,Premise,1310,1465,There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.,
17825417,Premise,1531,1661,Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).,
17825417,Claim,1810,1999,One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.,
17825417,Premise,1086,1240,At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).,
17825417,Premise,1241,1309,Visual acuity was similar for both groups at 3 months after surgery.,
17825417,Premise,667,870,Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).,
17825417,Premise,871,1085,After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).,
17947826,Premise,448,568,the overall probability of success of trabeculectomy and triple procedure was 0.613 and 0.733 at 15 years, respectively.,
17947826,Premise,569,709,The success probability of trabeculectomy and triple procedure in reducing IOP below 18 mm Hg was 0.748 and 0.825 at 15 years, respectively.,
17947826,Claim,710,838,In POAG and CPACG patients, trabeculectomy and triple procedure were effective in reducing IOP for up to 15 years after surgery.,
18164068,Premise,1235,1467,Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).,
18164068,Claim,1468,1594,Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.,
18164068,Premise,1595,1867,At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.,
18164068,Claim,1963,2099,Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.,
18327364,Premise,774,1024,The mean (standard error of mean [SE]) IOP reductions at months one was 7.2 (0.4), at month 3 was 7.3 (0.4), and at month 6 was 7.1 (0.3) mm Hg for the latanoprost group and 7.5 (0.3), 7.8 (0.3), and 7.4 (0.3) mm Hg for the dorzolamide/timolol group.,
18327364,Claim,1067,1189,The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline.,
18327364,Claim,1025,1066,The 2 therapies were similarly effective.,
18402717,Premise,1041,1238,Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).,
18402717,Premise,733,911,Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).,
18402717,Premise,1239,1361,Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.,
18402717,Claim,1362,1496,Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.,
18402717,Claim,1497,1543,Both adjunctive therapies were well tolerated.,
18402717,Premise,1544,1623,Limitations of this study include the use of a single site and the sample size.,
18402717,Claim,1624,1733,Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.,
18402717,Premise,912,1040,Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).,
1841578,Premise,472,655,Fifteen eyes (88%) in the mitomycin group and seven (47%) in the fluorouracil group achieved an intraocular pressure of less than or equal to 20 mm Hg without antiglaucoma medication.,
1841578,Premise,697,810,Corneal complications were less common in the group given mitomycin than in that given fluorouracil (12% vs 53%).,
1841578,Claim,811,883,The incidence of other complications was similar between the two groups.,
18603947,Premise,731,889,Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).,
18603947,Premise,890,1027,Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.,
18603947,Claim,1199,1262,Both the groups had a significant drop in IOP following surgery,
18603947,Premise,1273,1429,there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).,
18603947,Premise,1430,1558,There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.,
18603947,Claim,1559,1761,Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.,
18603947,Premise,1028,1071,Hypotony was noted in 3 eyes in each group.,
18826749,Premise,862,1142,The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).,
18826749,Premise,1143,1322,In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).,
18826749,Claim,1382,1472,a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.,
19092465,Premise,1167,1277,Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).,
19092465,Premise,1278,1396,The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).,
19092465,Premise,1761,1839,No statistical difference in terms of adverse events was found between groups.,
19092465,Claim,1996,2061,both fixed combinations are well tolerated with few side effects.,
19092465,Premise,1397,1532,Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.,
19092465,Claim,1840,1989,Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.,
19092465,Premise,1533,1651,After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.,
19123151,Premise,1043,1161,The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).,
19123151,Premise,1162,1347,A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.,
19123151,Claim,1348,1439,Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.,
19123151,Claim,1440,1522,BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.,
19243831,Premise,674,903,Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).,
19243831,Premise,904,1067,Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.,
19243831,Premise,1068,1241,Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.,
19243831,Claim,1242,1428,Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.,
19243831,Claim,1429,1510,Combined phacotrabeculectomy is associated with more postoperative complications.,
19336424,Premise,584,755,Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).,
19336424,Premise,797,939,however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).,
19336424,Premise,1021,1169,22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).,
19336424,Claim,1170,1300,Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.,
19336424,Claim,1301,1364,Both drugs were well tolerated with mild ocular adverse events.,
19336424,Premise,756,796,Adverse events were mild in both groups;,
19337705,Premise,1022,1207,At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.,
19337705,Premise,1208,1298,There was a similar level of postoperative interventions and complications for each group.,
19337705,Claim,1299,1506,In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.,
19337705,Claim,1507,1584,The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.,
19383599,Premise,1002,1088,The incidences of postoperative complications were similar between groups (p = 0.232).,
19383599,Premise,1089,1312,No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).,
19383599,Claim,1313,1498,In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.,
19383599,Claim,1499,1578,However, the combined surgery incurred fewer subsequent surgical interventions.,
19427617,Claim,786,882,Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.,
19427617,Premise,1057,1210,After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).,
19427617,Premise,1211,1454,Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.,
19427617,Claim,1455,1573,Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.,
19476406,MajorClaim,2,131,Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).,
19476406,Premise,1218,1437,At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).,
19476406,Premise,1438,1659,The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).,
19476406,Premise,1660,1816,Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.,
19476406,Claim,1817,1949,Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.,
19476406,Claim,1950,2014,Both fixed-combination medications were safe and well-tolerated.,
19590523,Premise,1030,1152,At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);,
19590523,Claim,1422,1528,Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.,
19590523,Premise,1153,1257,qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).,
19590523,Premise,1258,1421,Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.,
19860553,Premise,862,1009,The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.,
19860553,Premise,1016,1181,the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).,
19860553,Premise,1317,1401,there was a significant decrease in mean heart rate in the latanoprost/timolol group,
19860553,Premise,1412,1504,no significant changes in blood pressure and lung spirometry were observed in either groups.,
19860553,Claim,1505,1643,The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.,
19860553,Claim,1644,1813,Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.,
19900212,Premise,1193,1327,Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).,
19900212,Premise,1328,1389,No serious adverse events were judged to be treatment-related,
19900212,Premise,1391,1488,Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.,
19900212,Premise,1489,1586,Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.,
19900212,Claim,1587,1677,The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.,
19900212,Claim,1678,1782,Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.,
20092592,Premise,899,1036,The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).,
20092592,Premise,1194,1394,There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.,
20092592,Premise,1395,1605,The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.,
20092592,Claim,1606,1795,Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.,
20092592,Premise,1037,1193,Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).,
20142538,Premise,1153,1389,Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).,
20142538,Premise,1007,1152,FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.,
20142538,Premise,872,993,FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.,
20142538,Claim,1425,1611,Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.,
20142538,MajorClaim,1612,1725,Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.,
20142538,MajorClaim,1726,1824,The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.,
20142538,Claim,1390,1424,All therapies were well tolerated.,
20202537,Premise,1146,1399,At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).,
20202537,Claim,1400,1513,Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;,
20202537,Premise,993,1145,the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).,
20202537,Premise,802,992,The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;,
20420586,Claim,1300,1396,Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.,
20420586,Claim,908,986,the IOP-lowering effect during the study was slightly larger with latanoprost,,
20420586,Premise,737,898,Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).,
20420586,Premise,987,1260,this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).,
20472226,Claim,1545,1729,In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.,
20472226,Premise,1027,1234,IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).,
20472226,Premise,1235,1414,Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).,
20472226,Premise,1415,1544,There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.,
20472226,Claim,1730,1832,There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.,
20545217,Premise,422,656,Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).,
20545217,Premise,657,775,IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.,
20545217,Premise,776,887,A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.,
20545217,Claim,888,972,These results indicate that Tafluprost is clinically useful in the treatment of NTG.,
20584708,Premise,680,845,There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.,
20584708,Premise,846,1010,There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.,
20584708,Premise,1011,1141,CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.,
20584708,Premise,1142,1222,There was no significant difference in CCT increase in both groups at any visit.,
20584708,Premise,1238,1451,there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.,
20584708,Claim,1452,1549,Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.,
20584708,Claim,1550,1756,However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.,
20733558,Premise,773,937,At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).,
20733558,Claim,1470,1558,However, the bleb morphology caused more problems in the MMC group (avascularity score).,
20733558,Claim,1343,1469,The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.,
20733558,Premise,938,1102,No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.,
20733558,Premise,1103,1192,The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).,
20733558,Premise,1193,1342,After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).,
20828829,Premise,1229,1328,At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.,
20828829,Premise,1329,1451,Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).,
20828829,Premise,1452,1564,The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.,
20828829,Claim,1565,1804,Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.,
21034177,Claim,653,763,Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.,
21034177,Premise,764,972,Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.,
21034177,Premise,973,1283,IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.,
21034177,Claim,1284,1353,Ocular adverse and clinical success occurred equally with both drops.,
21034177,Claim,1354,1388,Both drops lowered IOP effectively,
21034177,Claim,1389,1475,but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.,
21034177,Premise,553,652,Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).,
21035866,Claim,1872,2010,This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.,
21035866,MajorClaim,30,254,neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).,
21035866,Premise,1286,1401,Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.,
21035866,Premise,1402,1553,The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.,
21035866,Claim,1554,1691,Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.,
21035866,Premise,1692,1871,Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).,
21141017,Premise,865,999,The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).,
21141017,Premise,1000,1123,Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).,
21141017,Premise,1124,1249,Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).,
21141017,Premise,1250,1376,Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.,
21141017,Claim,1427,1591,both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.,
21183518,Premise,707,835,125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.,
21183518,Claim,836,1025,The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).,
21183518,Premise,1026,1139,The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).,
21183518,Premise,1140,1325,Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).,
21183518,Claim,1326,1477,The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.,
21183518,Claim,1478,1559,Risk factors for pain include females, non-Chinese and previous cataract surgery.,
21257146,Claim,1637,1814,Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.,
21257146,Premise,1099,1283,Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).,
21257146,Premise,1284,1378,Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.,
21257146,Premise,1379,1538,More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).,
21257146,Claim,1539,1636,Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.,
21423036,Premise,958,1037,The mean IOP was significantly lower after 1 year in both the groups (P<0.001).,
21423036,Premise,1038,1157,The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).,
21423036,Premise,1158,1252,The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).,
21423036,Claim,1311,1500,Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.,
21423036,Premise,1501,1576,The mean IOP spike in the first month was lower in the triamcinolone group.,
21423036,Premise,1253,1310,Complication rates were not different between the groups.,
21491994,Premise,685,818,There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).,
21491994,Premise,819,1045,Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.,
21491994,Premise,1055,1190,there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).,
21491994,Premise,1191,1332,The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).,
21491994,Claim,1333,1552,Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.,
21491994,Claim,1553,1719,Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.,
21543992,Premise,919,1160,Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.,
21543992,Claim,1578,1704,These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.,
21543992,Premise,1161,1252,By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.,
21543992,Premise,1253,1344,There was not a statistically significant difference between the SLT and medication groups.,
21543992,Premise,1345,1415,IOP reduction was similar in both arms after 9 to 12-months follow-up.,
21573097,Claim,985,1050,TMMC and T5-FU appeared to have similar efficacy in lowering IOP.,
21573097,Premise,533,754,Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.,
21573097,Premise,832,894,statistical tests showed no difference in mean and median IOP.,
21573097,Premise,895,984,Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.,
21631670,Claim,1547,1660,Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.,
21631670,Premise,992,1217,At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).,
21631670,Premise,1218,1283,One patient in each group required Baerveldt device implantation.,
21631670,Premise,1284,1434,Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).,
21631670,Claim,1435,1546,Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.,
21680022,Claim,2039,2138,Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.,
21680022,Premise,1292,1448,Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).,
21680022,Premise,1449,1519,Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).,
21680022,Premise,1520,1687,Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.,
21680022,Premise,1688,1814,Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.,
21680022,Claim,1851,2038,Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.,
21680022,Claim,1815,1850,Both therapies were well tolerated.,
21701528,Claim,1522,1669,No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.,
21701528,Claim,1415,1521,Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.,
21701528,Premise,845,988,Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).,
21701528,Premise,989,1158,The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),,
21701528,Premise,1210,1414,The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.,
21792284,Claim,1911,2010,Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.,
21792284,Claim,1719,1910,Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.,
21792284,Premise,1625,1718,Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.,
21792284,Premise,1523,1624,Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.,
21792284,Premise,1244,1522,Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.,
21792284,Premise,1059,1243,The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).,
21921953,Claim,1527,1656,Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.,
21921953,Premise,1489,1526,No adverse reaction to OLO was noted.,
21921953,Premise,841,941,One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).,
21921953,Premise,942,1095,The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.,
21921953,Premise,1096,1203,The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.,
21921953,Premise,1204,1266,The bleb height in OLO group was higher than MMC one (P<0.05).,
21921953,Premise,1267,1488,SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.,
22310086,Claim,1811,1897,PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.,
22310086,Claim,1731,1810,The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.,
22310086,Premise,1603,1730,The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).,
22310086,Premise,1457,1602,Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).,
22310086,Premise,954,1120,IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.,
22310086,Premise,1121,1268,IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.,
22344189,Premise,755,962,At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).,
22344189,Premise,963,1161,The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).,
22344189,Premise,1162,1288,Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).,
22344189,Premise,1289,1499,Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.,
22344189,Claim,1500,1570,Trabeculectomy and Ex-PRESS implantation provided similar IOP control,,
22344189,Claim,1575,1701,the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.,
22458918,Claim,1522,1581,Both treatments demonstrated favorable ocular tolerability.,
22458918,Claim,1386,1521,Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.,
22458918,Premise,1108,1296,The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).,
22458918,Premise,975,1107,At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).,
22458918,Premise,1297,1385,Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.,
22775229,Claim,1547,1618,a 6-week treatment with LT or BT was equally effective in reducing IOP.,
22775229,Claim,1632,1724,none of the administered drugs induced a significant effect on ocular blood flow parameters.,
22775229,Premise,1121,1233,Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).,
22775229,Premise,1247,1358,no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).,
22775229,Premise,1359,1422,Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment),
22775229,Premise,1427,1524,no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.,
22814041,Claim,1555,1616,Both groups had a similar favorable long-term safety profile.,
22814041,Premise,647,733,The incidence of adverse events was low in both groups through 24 months of follow-up.,
22814041,Premise,734,926,At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).,
22814041,Premise,936,1158,the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.,
22814041,Premise,1159,1356,Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.,
22814041,Claim,1357,1554,Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.,
22835512,Claim,1963,2125,The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.,
22835512,Claim,1782,1962,This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.,
22835512,Premise,922,1071,Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).,
22835512,Premise,1460,1563,randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).,
22835512,Premise,1570,1644,randomization to brimonidine 0.2% was protective compared to timolol 0.5%,,
22835512,Premise,1646,1781,ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.,
22835512,Premise,1141,1451,older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression,
22986111,Claim,1343,1485,Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.,
22986111,Claim,1215,1342,Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.,
22986111,Premise,1137,1214,Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.,
22986111,Premise,1013,1136,trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).,
22986111,Premise,869,1003,Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).,
22986111,Premise,648,868,Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).,
23059481,Claim,1377,1523,The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.,
23059481,Premise,1229,1375,There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).,
23059481,Premise,1077,1177,The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);,
23059481,Premise,1178,1228,hypotony recovered in 80.8% (21/26) within 1 week.,
23059481,Premise,757,1003,The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),,
23059481,Premise,1008,1076,no difference was observed after the second week (P=0.659 to 0.753).,
23059481,Claim,1524,1636,Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.,
23203707,Claim,1253,1343,Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.,
23203707,Premise,1085,1252,Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).,
23203707,Premise,936,1084,Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).,
23203707,Premise,803,935,The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.,
23203707,Premise,612,754,Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.,
23285843,Claim,862,945,Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,,
23285843,Claim,946,1026,although its IOP-lowering effect was inferior to topical timolol as monotherapy.,
23285843,Premise,381,499,The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).,
23285843,Premise,500,649,The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.,
23285843,Premise,650,807,When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).,
23429621,Claim,1273,1333,Both drops provided effective IOP reduction that was greater,
23429621,Claim,1338,1423,patients were more likely to achieve lower target pressures with BTFC than with TTFC.,
23429621,Premise,653,752,Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).,
23429621,Premise,753,855,BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).,
23429621,Premise,856,1002,Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.,
23429621,Premise,1003,1272,IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).,
28178150,Premise,905,1090,eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).,
28178150,Premise,1395,1525,Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).,
28178150,Premise,1526,1635,Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).,
28178150,Claim,1768,1827,the SLT's effect was significant only during the nighttime.,
28178150,Claim,1636,1761,The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,,
28178150,Claim,1828,1915,Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.,
28178150,Claim,1945,2029,travoprost better controls IOP fluctuations than SLT, especially during the daytime.,
8058290,Premise,640,778,Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).,
8058290,Premise,779,903,The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).,
8058290,Premise,904,1094,The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).,
8058290,Claim,1095,1141,Complication rates were statistically similar.,
8058290,Claim,1362,1535,The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications,
8058290,Claim,1537,1621,although the larger implant was associated with a higher rate of some complications.,
8058290,Claim,1631,1747,the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.,
8058290,Premise,1142,1361,The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).,
8628543,Premise,633,839,Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.,
8628543,Premise,918,1036,Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.,
8628543,Premise,1046,1087,both drugs were generally well tolerated.,
8628543,Premise,1088,1217,The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).,
8628543,Claim,1218,1277,Timolol caused more systemic side effects than latanoprost.,
8628543,Claim,1278,1406,Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.,
8628543,Claim,1407,1476,Latanoprost was generally well tolerated systemically and in the eye.,
8628544,Premise,944,1020,Pulse rate was significantly reduced with timolol, but not with latanoprost.,
8628544,Premise,1021,1125,Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.,
8628544,Claim,1126,1193,Fewer subjective side effects occurred in latanoprost-treated eyes.,
8628544,Claim,1538,1674,no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.,
8628544,MajorClaim,1675,1758,Latanoprost has the potential for becoming a new first-line treatment for glaucoma.,
8628544,Premise,425,575,Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.,
8628544,Premise,576,809,Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).,
8628544,Premise,1194,1438,Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.,
9034838,Premise,794,956,Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).,
9034838,Premise,957,1134,There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).,
9034838,Premise,1304,1428,No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).,
9034838,Claim,1634,1696,There was no difference in hyperemia between the two regimens.,
9034838,Claim,1697,1787,Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.,
9034838,Premise,1429,1537,Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).,
9034838,Premise,1135,1303,There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).,
9034838,Claim,1538,1633,Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.,
9230823,Premise,668,850,Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.,
9230823,Premise,851,948,Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03),
9230823,Premise,1085,1139,No evidence of tachyphylaxis was seen in either group.,
9230823,Premise,1140,1200,Allergy was seen in 9% of subjects treated with brimonidine.,
9230823,Premise,1201,1311,Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),,
9230823,Premise,1455,1518,Headache, fatigue, and drowsiness were similar in the 2 groups.,
9230823,Claim,1575,1646,Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.,
9230823,Claim,1647,1776,Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.,
9230823,Premise,1316,1454,complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).,
